Search hospitals > Maine > Augusta
Harold Alfond Center for Cancer Care
Claim this profileAugusta, Maine 04330
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
147 reported clinical trials
10 medical researchers
Summary
Harold Alfond Center for Cancer Care is a medical facility located in Augusta, Maine. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Harold Alfond Center for Cancer Care is involved with conducting 147 clinical trials across 239 conditions. There are 10 research doctors associated with this hospital, such as Sarah J. Sinclair, Leslie Bradford, MD, Peter Rubin, and Rachit Kumar.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
Stage IV
Top PIs
Sarah J. SinclairLafayette Family Cancer Center-EMMC4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
78 reported clinical trials
155 drugs studied
Leslie Bradford, MDMaine Medical Center- Scarborough Campus3 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
19 reported clinical trials
49 drugs studied
Peter RubinMaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford5 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
17 reported clinical trials
42 drugs studied
Rachit KumarHarold Alfond Center for Cancer Care1 year of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
46 drugs studied
Clinical Trials running at Harold Alfond Center for Cancer Care
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Ovarian Cancer
Fallopian Tube Cancer
Solid Tumors
Colorectal Cancer
Peritoneal Cancer
Serous Cystadenocarcinoma
Online Sexual Health Program
for Breast Cancer Survivors
The goal of this clinical trial is to develop an effective internet-delivered program to help breast cancer survivors manage cancer-related sexual concerns. This study is being done to find out if the study approach is better or worse than the usual approach to helping breast cancer survivors manage cancer-related sexual concerns. The usual approach is defined as care most cancer survivors get for their cancer-related sexual concerns. Participants will complete a questionnaire and if they qualify, they will be assigned to one of sixteen groups of participants. Groups will get access to various kinds of help through an Internet-delivered program called SHINE, which was designed and is run by researchers at the University of Virginia Center for Behavioral Health and Technology. All groups will get access to education about sexual health after cancer: either a standard education website or an enhanced education web program. Groups may also receive up to three additional web programs on: talking to your clinicians about sexual concerns, and/or talking to your partner about sexual concerns, and/or increasing intimacy. Participants are asked to complete the SHINE program within 12 weeks. After participants finish this 12-week period, the study team will ask them to complete a questionnaire to check in with the participant. The participant will be asked one additional time 12 weeks later to complete another questionnaire to see how the participant is doing. A participant will be in the study for 24 weeks.
Recruiting1 award N/A
Targeted Therapy
for Solid Tumors
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Recruiting1 award Phase 217 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Harold Alfond Center for Cancer Care?
Harold Alfond Center for Cancer Care is a medical facility located in Augusta, Maine. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. Harold Alfond Center for Cancer Care is involved with conducting 147 clinical trials across 239 conditions. There are 10 research doctors associated with this hospital, such as Sarah J. Sinclair, Leslie Bradford, MD, Peter Rubin, and Rachit Kumar.